Faculty of Medicine and Health, University of Sydney School of Health Sciences, Sydney, New South Wales, Australia.
Paediatric Gait Analysis Service of New South Wales, Sydney Children's Hospitals Network, Westmead, New South Wales, Australia.
J Peripher Nerv Syst. 2024 Jun;29(2):185-192. doi: 10.1111/jns.12619. Epub 2024 Mar 6.
Riboflavin transporter deficiency (RTD) is a progressive inherited neuropathy of childhood onset, characterised clinically by pontobulbar palsy, sensory ataxia, sensorineural deafness, muscle weakness, optic atrophy and respiratory failure. A robust and responsive functional outcome measure is essential for future clinical trials of disease-modifying therapies including genetic therapies. The Charcot-Marie-Tooth disease Pediatric Scale (CMTPedS) is a well-validated outcome measure for CMT and related neuropathies, and might have utility for measuring disease progression in individuals with RTD. However, the CMTPedS requires modifications to account for phenotypic differences between children with CMT and RTD. The aim of this study was to develop a functional outcome measure based on the CMTPedS for specific use in individuals with RTD.
The CMTPedS data collected over the last 10 years in individuals with RTD attending the Peripheral Neuropathy Management Clinic at the Children's Hospital at Westmead (Sydney, Australia) were reviewed to evaluate each item within the CMTPedS. A literature review of articles published until September 2021 for functional outcome measures generated an item pool for pilot testing. The results of this pilot testing, alongside analysis of existing CMTPedS item scores in the RTD cohort, informed the modification of the CMTPedS.
CMTPedS data were reviewed for eight individuals over the past 10 years. Two items were identified as requiring modification or removal and additional items of proximal strength and function needed to be considered. Six studies were identified in the literature review, and five items were selected for pilot testing. 'Shoulder internal rotation' and the '30-s sit to stand test' were added as proximal measures of strength and function. The composite balance item comprising nine tasks in the CMTPedS showed a ceiling effect and was replaced with the single 'Feet apart on a line eyes open' balance item. 'Pinprick sensation' was removed due to a floor effect.
This study provides preliminary evidence that the Riboflavin Transporter Deficiency Pediatric Scale (RTDPedS) is a functional outcome measure covering strength, upper and lower limb function, balance and mobility for individuals with RTD to assess disease severity and progression in clinical trials and cohort studies.
核黄素转运蛋白缺乏症(RTD)是一种进行性遗传性儿童起病的周围神经病,临床上表现为延髓性麻痹、感觉性共济失调、感觉神经性耳聋、肌肉无力、视神经萎缩和呼吸衰竭。对于包括基因治疗在内的疾病修饰疗法的未来临床试验,需要一种强大且敏感的功能预后指标。Charcot-Marie-Tooth 疾病小儿量表(CMTPedS)是一种经过充分验证的用于 CMT 和相关神经病变的预后指标,可能对评估 RTD 个体的疾病进展有用。然而,CMTPedS 需要进行修改,以考虑 CMT 和 RTD 患儿之间的表型差异。本研究旨在开发一种基于 CMTPedS 的功能预后指标,专门用于 RTD 患者。
回顾过去 10 年在西悉尼儿童医院周围神经病管理诊所就诊的 RTD 患者的 CMTPedS 数据,以评估 CMTPedS 中的每个项目。对截至 2021 年 9 月发表的关于功能预后指标的文章进行文献回顾,生成了一个试点测试的项目池。该试点测试的结果以及对 RTD 队列中现有 CMTPedS 项目得分的分析,为 CMTPedS 的修改提供了信息。
过去 10 年中,对 8 名患者的 CMTPedS 数据进行了回顾。确定了需要修改或删除的两个项目,并需要考虑额外的近端力量和功能项目。文献综述中确定了 6 项研究,选择了 5 项进行试点测试。“肩部内旋”和“30 秒坐站测试”被添加为近端力量和功能的测量指标。CMTPedS 中包含 9 项任务的综合平衡项目存在天花板效应,被替换为单一的“睁眼单脚站在线上”平衡项目。由于存在地板效应,“刺痛觉”被删除。
本研究初步证明,核黄素转运蛋白缺乏症小儿量表(RTDPedS)是一种针对 RTD 患者的功能预后指标,涵盖力量、上下肢功能、平衡和移动能力,可用于临床试验和队列研究中评估疾病严重程度和进展。